Virbac in the news

Virbac's Thai subsidiary celebrates 30 years, expecting 13 million euros in revenue by 2025, driven by strategic focus on swine farming, pet care, and aquaculture.

Virbac published its September 2026 declaration detailing the total number of shares and voting rights, as required by French financial regulations.

Virbac declared its total number of shares and voting rights as of September 2026, adhering to French Financial Market Authority regulations.

Virbac published its September 2026 declaration detailing the total number of shares and voting rights, as per French financial regulations.

Virbac's Thai subsidiary celebrates 30 years of operation, expecting €13 million in revenue by 2025 by focusing on pig farming, companion animals, and aquaculture.

Virbac's stock rose 2.36% to —314.25, recovering after an initial 5.5% drop following strong first-half results and confirmed high-end 2026 objectives, and now trades above its 20-day moving average.

Virbac's stock rose by 2.36% to –314.25, surpassing its 20-day moving average, driven by strong half-yearly results and a share buyback program, despite an earlier 5.5% decline post-results.

Virbac confirmed its 2026 outlook, expecting higher revenue growth after strong first-half results, which saw increased sales in both companion and farm animal segments and a rise in stock price.

Virbac's stock shows signs of a potential trend change despite being in a downtrend, with trading volumes below average and key support and resistance levels identified.

Virbac confirmed its 2026 revenue outlook at the high end, backed by strong first-half performance, despite its stock remaining below its yearly peak.

This document provides analyst insights, price targets, and recommendations for Virbac SA (VRBCF).

Virbac hosted a symposium in Edinburgh with feline medicine specialists to discuss early detection and coordinated management of comorbidities in aging cats.

VIRBAC SA shows a clear downward trend in both mid and short-term forecasts, with specific price targets and resistance levels.

Virbac's stock rose 0.90% after-hours on October 2, 2026, following a strong first half of 2026 with 7.4% revenue growth and increased profits, and the company confirmed its full-year guidance.

Virbac's stock saw a slight daily increase of 0.49% on the Paris Stock Exchange, closing at 308.000  , despite a 4.64% drop over the last year.

Virbac gathered 100 feline specialists in Edinburgh to discuss senior cat health, focusing on early detection and management of age-related diseases.

This document details the EBITDA per share for Virbac SA, referencing its HAN:V16 ticker and crediting data sources.

Virbac confirmed its 2026 revenue growth outlook, supported by strong first-half results, with stock trading at EUR 308.75.

Virbac hosted an international symposium in Edinburgh for feline medicine specialists to discuss advanced care, prevention, and nutrition for senior cats facing complex health challenges.

Virbac's share price dropped by 2.09% to 305 euros, briefly breaking its 302 euro support, despite strong H1 2026 results and reinforced governance.